Thieler Law Corp advises investors with losses exceeding $100,000 of the April 26, 2019 lead plaintiff deadline in a class action lawsuit filed against AVEO Pharmaceuticals Inc (NASDAQ: AVEO) (“Aveo” or “the Company”). The suit is pending in the U.S. District Court for the Southern District of New York and investors, who purchased AVEO Pharmaceuticals Inc securities between August 4, 2016 and January 31, 2019, have until April 26, 2019 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class.

If you purchased AVEO Pharmaceuticals Inc securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class.

The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that the TIVO‑3 trial was inadequately designed to address the OS concerns regarding AVEO's lead candidate drug, tivozanib, from the TIVO-1 trial presented in the June 2013; tivozanib had insufficient survival data to meet FDA approval following its initial 2013 rejection; this lack of sufficient survival data would put tivozanib at greater risk of delayed FDA approval; and as a result, AVEO's public statements were materially false and misleading at all relevant times.

On January 31, 2019, the Company revealed it would not file a New Drug Application for tivozanib (FOTIVDA®). According to AVEO, the FDA indicated that these “preliminary OS results do not allay their concerns about the potential detriment in OS outlined in the complete response letter dated June 6, 2013.” AVEO “plans to make a NDA filing decision following the availability of more mature OS results.”

Following this news, NASDAQ: AVEO fell $1.07 per share, or over 60%, to close at $0.70 per share on January 31, 2019.

If you were negatively impacted by your investment in AVEO Pharmaceuticals Inc securities between August 4, 2016 and January 31, 2019 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Materials are provided for informational purposes only and do not constitute legal advice. We are only licensed to practice law in Germany. We are neither licensed nor qualified to render advice on US Federal or State law.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/

or

Facsimile: +1 (619) 785 – 3185